BioSpace News Archive

SoniVie Ltd., a medical device company developing a proprietary solution to treat hypertension, announced the completion of a $60 million series C round financing.

Kernal Biologics, Inc. today announced it is presenting in person at Biotech Showcase™, the investor conference for innovators.

Viking Therapeutics, Inc. today announced the completion of patient enrollment in its Phase 2b clinical trial of VK2809, the company’s novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH).

Opticyte Earns FDA Breakthrough Device Designation for the First Cell O 2 Patient Monitor for Organ Failure.

AlloVir, Inc. today announced the company’s 2023 priorities and anticipated future milestones across its pipeline of virus-specific T cell therapies, including its lead investigational therapy posoleucel.

Twist Bioscience Corporation today announced a research collaboration with Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) to discover antibodies against multiple targets of interest to develop curative therapies for patients suffering from diseases that lack treatment options.

The merger of equals between Orthofix Medical Inc. (“Orthofix”) and SeaSpine Holdings Corporation (“SeaSpine”) became effective as of January 5, 2023.

Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today outlined anticipated 2023 milestones ahead of its participation at the 41st Annual J.P. Morgan Healthcare Conference.

Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced the initiation of the VEGA-2 Phase 3 pivotal trial with the first patient enrolled in late December.

iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, outlined business updates that are anticipated to advance its position in 2023, building a path to registration for its promising immunotherapy portfolio.